The Differences of Complications Between LPD(Laparoscopic Pancreaticoduodenectomy) and OPD(Open Pancreaticoduodenectomy)
TDCBLAP
To Investigate The Difference of Complications and Short-term Prognosis Between Laparoscopic and Open Pancreaticoduodenectomy in Patients With Pancreatic Cancer Based on a Special Disease Cohort Database
1 other identifier
observational
220
1 country
1
Brief Summary
Main objective: This project intends to design a simulated RCT project and clinically relevant RCT study to target, selecting the study titled "Short-Term outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial (Short-term Outcomes of Laparoscopic versus Open Pancreaticoduodenectomy in Patients with Pancreatic Ductal Adenocarcinoma)", use the cases in the Pancreatic Cancer Special Disease Cohort Database, compare the differences in complications and short-term prognosis between patients with pancreatic cancer after laparoscopic and open pancreaticoduodenectomy, investigate the efficacy and safety of laparoscopic pancreaticoduodenectomy, and provide the basis and reference of real-world data for clinical relevant studies. Secondary objective: To predict the incidence of postoperative complications and short-term outcomes of pancreatic cancer patients by comparing the difference of complications and short-term prognosis between laparoscopic and open pancreaticoduodenectomy, and to improve the treatment power of patients scheduled for surgery and postoperative patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedFirst Submitted
Initial submission to the registry
November 10, 2024
CompletedFirst Posted
Study publicly available on registry
November 13, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2025
CompletedNovember 13, 2024
November 1, 2024
3 years
November 10, 2024
November 11, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Overall survive
from the day after surgery to 3 years
complication
any possible symptoms caused by surgery
during the days Postoperative up to 1 year
Study Arms (1)
OPD
The patients who received the OPD
Interventions
Eligibility Criteria
All patients treated with LPD or OPD for pancreatic cancer in Huadong Hospital from 1,January 2020 to 31,December 2022
You may qualify if:
- Age: 18 years old, with no gender limit;
- Histologically confirmed or clinically diagnosed as pancreatic cancer by MDT (multidisciplinary team), without histopathological evidence;
- Patients may receive LPD or OPD according to the MDT evaluation;
- Patients understand and are willing to comply with the trial;
- Signed written informed consent before patient enrollment;
- Patients who meet the clinical guidelines for intent to treat.
- Those who met each of the above criteria were included in the study.
You may not qualify if:
- Patients with distant metastasis found before or during surgery, including peritoneal, liver, distant lymph node metastasis, and other organ involvement;
- Patients who need pancreatic neck or pancreatic tail, total pancreatic resection or other palliative surgery;
- Preoperative anesthesia ASA score of 4 points;
- A history of other malignant tumors;
- Pregnant or lactating women;
- Patients with severe mental disorders;
- MDT evaluates patients with vascular invasion and requiring vascular resection based on abdominal imaging data;
- Patients who have participated in other clinical trials within 3 months. Those who meet any of the above criteria were not included in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Zhijun Baolead
- Ruijin Hospitalcollaborator
Study Sites (1)
Huadong Hospital
Shanghai, China
Biospecimen
Pathological tissue,blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Dean
Study Record Dates
First Submitted
November 10, 2024
First Posted
November 13, 2024
Study Start
January 1, 2020
Primary Completion
December 31, 2022
Study Completion
July 31, 2025
Last Updated
November 13, 2024
Record last verified: 2024-11